Trial reportAllergy2010
CC chemokine receptor 4 (CCR4) in human allergen-induced late nasal responses.
Trial report in Allergy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 44 citations in OpenAlex.
- Safety, tolerability, pharmacokinetics and pharmacodynamics of GSK2239633, a CC-chemokine receptor 4 antagonist, in healthy male subjects: results from an open-label and from a randomised study.BMC pharmacology & toxicology · 2013Trial
- Characterizing the symptomatology and pathophysiology of allergic rhinitis using a nasal allergen challenge model - a subset of the allergic rhinitis microbiome study.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2025Article
- Unravelling allergic rhinitis: exploring pathophysiology, advances in treatment, and future directions.Frontiers in allergy · 2025Review
- Prognostic Role of Neutrophil to Lymphocyte Ratio in Allergic Rhinitis: A Systematic Review and Meta-analysis.Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2024Article
- T-cell subset changes during the first year of pre-seasonal allergoid allergen-specific immunotherapy.Heliyon · 2023Article
- CC Chemokine Receptor 4 (CCR4) as a Possible New Target for Therapy.International journal of molecular sciences · 2022Review
- Chemokines and chemokine receptors in allergic rhinitis: from mediators to potential therapeutic targets.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2022Review
- A high-throughput chemotaxis detection method for CCR4Journal of immunological methods · 2020Article
- Alternatively activated macrophages; a double-edged sword in allergic asthma.Journal of translational medicine · 2020Review
- A new antagonist for CCR4 attenuates allergic lung inflammation in a mouse model of asthma.Scientific reports · 2017Article
- Targeting chemokine receptors in disease--a case study of CCR4.European journal of pharmacology · 2015Review
- Increased proportions of CCR4(+) cells among peripheral blood CD4(+) cells and serum levels of allergen-specific IgE antibody in canine chronic rhinitis and bronchitis.The Journal of veterinary medical science · 2015Article
- Local and systemic effects of cat allergen nasal provocation.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2015Article
- A role for CCL28-CCR3 in T-cell homing to the human upper airway mucosa.Mucosal immunology · 2015Article
- Lower serum levels of Th2-related chemokine CCL22 in women patients with multiple sclerosis: a comparison between patients and healthy women.Inflammation · 2014Article
- Distinct conformations of the chemokine receptor CCR4 with implications for its targeting in allergy.Journal of immunology (Baltimore, Md. : 1950) · 2014Article
- An imbalance between frequency of CD4+CD25+FOXP3+ regulatory T cells and CCR4+ and CCR9+ circulating helper T cells is associated with active perennial allergic conjunctivitis.Clinical & developmental immunology · 2013Article
- Chemokine-like factor 1 (CLFK1) is over-expressed in patients with atopic dermatitis.International journal of biological sciences · 2013Article
- Highly interconnected genes in disease-specific networks are enriched for disease-associated polymorphisms.Genome biology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundCC Chemokine receptor 4 (CCR4) is preferentially expressed on Th2 lymphocytes. CCR4-mediated inflammation may be important in the pathology of allergic rhinitis. Disruption of CCR4 - ligand interaction may abrogate allergen-induced inflammation.
methodsSixteen allergic rhinitics and six nonatopic individuals underwent both allergen and control (diluent) nasal challenges. Symptom scores and peak nasal inspiratory flow were recorded. Nasal biopsies were taken at 8 h post challenge. Sections were immunostained and examined by light or dual immunofluorescence microscopy for eosinophils, T-lymphocytes, CCR4(+)CD3(+) and CXCR3(+)CD3(+) cells and examined by in situ hybridization for CCR4, IL-4 and IFN-gamma mRNA(+) cells. Peripheral blood mononuclear cells were obtained from peripheral blood of nine normal donors and the CCR4(+)CD4(+) cells assessed for actin polymerization in response to the CCR4 ligand macrophage-derived chemokine (MDC/CCL22) and the influence of a CCR4 antagonist tested.
resultsAllergic rhinitics had increased early and late phase symptoms after allergen challenge compared to diluent; nonatopics did not respond to either challenge. Eosinophils, but not total numbers of CD3(+) T cells, were increased in rhinitics following allergen challenge. In rhinitics, there was an increase in CCR4(+)CD3(+) protein-positive cells relative to CXCR3(+)CD3(+) cells; CCR4 mRNA+ cells were increased and IL-4 increased to a greater extent than IFN-gamma. CCR4(+)CD4(+) T cells responded to MDC in vitro, and this response was inhibited by the selective CCR4 antagonist.
conclusionLymphocyte CCR4 expression is closely associated with induction of human allergen-induced late nasal responses. Blocking CCR4-ligand interaction may provide a novel therapeutic approach in allergic disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.